InflaRx (NASDAQ:IFRX – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare InflaRx to related companies based on the strength of its dividends, analyst recommendations, institutional ownership, profitability, earnings, valuation and risk.
Insider and Institutional Ownership
42.4% of InflaRx shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Risk and Volatility
InflaRx has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500. Comparatively, InflaRx’s rivals have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.
Profitability
This table compares InflaRx and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InflaRx | N/A | -53.56% | -43.02% |
| InflaRx Competitors | -9,051.23% | -201.20% | -30.64% |
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for InflaRx and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InflaRx | 1 | 2 | 5 | 1 | 2.67 |
| InflaRx Competitors | 9792 | 15073 | 45355 | 1574 | 2.54 |
InflaRx currently has a consensus price target of $7.43, indicating a potential upside of 428.72%. As a group, “Biotechnology” companies have a potential upside of 96.31%. Given InflaRx’s stronger consensus rating and higher probable upside, equities research analysts clearly believe InflaRx is more favorable than its rivals.
Earnings & Valuation
This table compares InflaRx and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| InflaRx | $30,000.00 | -$51.63 million | -2.42 |
| InflaRx Competitors | $727.61 million | $12.25 million | -10.24 |
InflaRx’s rivals have higher revenue and earnings than InflaRx. InflaRx is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
InflaRx beats its rivals on 8 of the 13 factors compared.
About InflaRx
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.
